Biogen is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. The company focuses on addressing serious conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, among others. Through advanced research and development, Biogen aims to create breakthrough treatments that improve the lives of patients and their families, and it leverages its expertise in biologics and immunology to bring novel solutions to market. Additionally, Biogen is committed to advancing science and fostering collaboration within the medical and scientific communities to further enhance patient care. Read More
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.
CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s research and development and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR). TRANSCEND is designed to enroll approximately 120 kidney transplant recipients with late AMR.
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025, before final recommendations are issued.
Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing the impact.
